INFINIUM
Infinium Pharma financials
- Market cap
- ₹427 Cr
- Sector
- Healthcare
What Infinium Pharma does
Infinium PharmaChem manufactures iodine-based derivatives, intermediates and APIs at its GIDC Sojitra (Anand, Gujarat) plant, supplying pharmaceutical, agrochemical, nutraceutical and specialty-chemical customers under a CRAMS (custom research and manufacturing) model across 30+ export countries. It secures its key raw material through a US joint venture (IBL Elements Inc., Texas) that extracts iodine from oilfield brine under a 30-year supply agreement, and is building a new facility to forward-integrate into contrast-media intermediates such as Atipa dichloride for medical-imaging use. Group entities extend the business into API trading (Infinium Healthcare Pvt Ltd), bio-coal/biomass fuel (Infinium Green Energy Pvt Ltd) and cross-border chemical trading with China (Shanghai Tajilin JV).
Segments
- Iodine derivatives & APIs
- Contrast media (under development)
- API trading
- Bio-coal / green energy
- China trading JV
- Installed manufacturing capacity
- 1,800 MTPA (iodine derivatives, GIDC Sojitra plant, Gujarat)
- Annual production volume
- 293 MT
- Product portfolio
- 220+ iodine derivatives
- APIs manufactured
- 19
- Export footprint
- 30+ countries
- Captive iodine supply
- ~120 MT/year via 30-year JV with IBL Elements Inc. (US brine extraction)
Quarterly results
Q4 FY26: revenue up 16.7%, net profit up 0.0% against the same quarter last year.
| Line item | Q2 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 58 | 51 | 72 | 71 | 66 +14% | 73 +43% | 84 +17% |
| EBITDA | 8 | 10 | 8 | 7 | 8 +0% | 9 −10% | 8 +0% |
| Net profit | 5 | 6 | 5 | 4 | 5 +0% | 5 −17% | 5 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +3.9% 1Y
1Y: ₹256.25 on 10 Sept 2025 → ₹266.2. High ₹283 (9 Sept 2026), low ₹191.05 (12 Jun 2026).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹1 Cr | ₹1 Cr | ₹5 Cr | ₹14 Cr | ₹16 Cr | ₹16 Cr |
| Reserves | ₹6 Cr | ₹12 Cr | ₹17 Cr | ₹44 Cr | ₹99 Cr | ₹100 Cr |
| Borrowings | ₹11 Cr | ₹23 Cr | ₹26 Cr | ₹8 Cr | ₹0 Cr | ₹0 Cr |
| Other liabilities | ₹13 Cr | ₹14 Cr | ₹13 Cr | ₹12 Cr | ₹75 Cr | ₹25 Cr |
| Total liabilities | ₹31 Cr | ₹49 Cr | ₹60 Cr | ₹78 Cr | ₹190 Cr | ₹141 Cr |
| Fixed assets | ₹4 Cr | ₹4 Cr | ₹16 Cr | ₹16 Cr | ₹24 Cr | ₹17 Cr |
| Capital work in progress | ₹4 Cr | ₹8 Cr | ₹0 Cr | ₹0 Cr | ₹5 Cr | ₹7 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹29 Cr | ₹16 Cr |
| Other assets | ₹22 Cr | ₹37 Cr | ₹44 Cr | ₹61 Cr | ₹132 Cr | ₹101 Cr |
| Total assets | ₹31 Cr | ₹49 Cr | ₹60 Cr | ₹78 Cr | ₹190 Cr | ₹141 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Mar 2025, promoters trimmed −0.33 pp while DIIs added +0.21 pp. The shareholder count grew 11% to 1,061.
- Promoters
- 64.9%
- DIIs
- 0.2%
- Public
- 34.9%
Since Mar 2025
- Promoters −0.33 pp
- DIIs +0.21 pp
- Public +0.11 pp
How it drifted, 7 quarters
Over this window promoters fell from 73.0% to 64.9% — −8.1 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 73.0%, Public 26.9%.Mar '24: Promoters 73.0%, Public 26.9%.Sep '24: Promoters 73.0%, Public 26.9%.Nov '24: Promoters 65.2%, Public 34.8%.Mar '25: Promoters 65.2%, Public 34.8%.Sep '25: Promoters 59.9%, DIIs 0.0%, Public 40.1%.Mar '26: Promoters 64.9%, DIIs 0.2%, Public 34.9%.
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Bhadabhai Kacharabhai Madhani newly disclosed 0.00% held
The same filing shows 2 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Infinium Pharma above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Pravin Bhadabhai Madhani | 21.66% | unchanged |
| Sanjaykumar Viththalbhai Patel | 10.25% | unchanged |
| Lavjibhai Ramjibhai Chikhaliya | 7.60% | unchanged |
| Madhani Krunal Pravinbhai | 5.00% | unchanged |
| Mitesh Lavjibhai Chikhaliya | 4.78% | unchanged |
| Ashish Kacholia | 4.62% | unchanged |
| Ashish Agarwal Individual | 4.62% | unchanged |
| Daxa Sanjaykumar Patel | 3.68% | unchanged |
| Bharat Khodabhai Madhani | 3.28% | unchanged |
| Varshaben Pravinbhai Madhani | 2.35% | unchanged |
| Shardaben Lavjibhai Chikhaliya | 2.00% | unchanged |
| Dipen Babulal Dobariya | 1.61% | −0.29 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 15.7% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse Infinium Pharma
Guides on how to read this kind of business and the numbers that matter.